Genfit S.A. (GNFT) wants to splice the loose ends of your portfolio as the gene editor hits the Nasdaq this week. The stock could debut as soon as Wednesday, according to IPO Scoop.
Genfit is expected to issue 5 million shares at $26.33 apiece representing 13.8 percent of its outstanding shares. The firm has been listed on Euronext Paris since 2006.
In the U.S., it qualifies as an emerging growth company under the JOBS Act, which entitles management to less stringent disclosure standards.
Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here
Since its 1999 inception in France, the late-stage biopharmaceutical company has created treatments and diagnostics targeting metabolic and liver-related diseases. Its nuclear receptor-based platform has so far yielded candidates for nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH-induced fibrosis and IL-17 autoimmune diseases.